Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 3
18+
2 sites in NV, OH
What this study is about
This Phase 3 study is testing gemcitabine in people with pancreatic adenocarcinoma. The primary outcome being measured is Overall survival (OS).
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
gemcitabine, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
injection (Injection), infusion
Primary: Overall survival (OS), Progression free survival (PFS)
Secondary: Duration of response (DOR), Health-related outcome assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Pancreatic Cancer Module (EORTC QLQ-PAN26), Incidence of adverse events (AEs), Objective response rate (ORR), Quality of life as assessed with European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Oncology